Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Amsterdam UMC, location VUmc
Age
Any age
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
1. Cytologically or histologically confirmed stages II or III non-squamous NSCLC
2. No evidence of tumour invading major blood vessels and no active hemoptysis (bright red blood of at least ½ teaspoon) in the 28 days prior to randomization.
3. No prior systemic therapy for NSCLC. Prior surgery and/or extra-thoracic irradiation is permitted.
4. Presence of at least one measurable target lesion
5. Age 18 or greater.
6. WHO performance status of 0 or 1.
7. Acceptable pulmonary function as defined by a Fev1 of ≥30% and a DLCO of ≥40% of predicted
8. Life expectancy of at least 12 weeks.
9. Adequate hematological, renal and hepatic functions
* Absolute neutrophil count \>2x109/l.
* Platelet count \> 100x109/l.
* Total bilirubin \< 1.5 x UNL
* ASAT/ALAT \< 2 x UNL
* Alkaline phosphatase \< 5 x UNL
* Creatinine \< 130 μmol/L
* Creatinine clearance \> 60 ml/min; measured or calculated
10. Urine dipstick for proteinuria \< 1+. If urine dipstick is ≥ 1, 24 hour urine must demonstrate \< 500 mg of protein in 24 hours.
11. No pre-existing sensory neurotoxicity grade 2 (CTC)
12. No active (uncontrolled) infection requiring antibiotics
You may not be if
1. Mixed tumor types with small cell lung cancer or squamous cell carcinoma
2. Other serious diseases, such as heart failure, angina pectoris, myocardial infarction within the last 6 months, uncontrolled hypertension
3. Serious non-healing wound or ulcer.
4. ASAT and ALAT \> 1,5 x UNL
5. alkaline phosphatase 5 x UNL
6. Evidence of bleeding diathesis or coagulopathy.
7. Any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule; those conditions should be assessed with the patient before registration in the trial.
8. Participation in other trial with investigational drug or treatment modality.
Clareo Health | Safety Study of Bevacizumab (Avastin) With Thoracic Radiation in Non-small Cell Cell Lung Cancer
